诱导后流式与GATA1-PCR检测的MRD是唐氏综合征髓系白血病的重要预后因素
日本儿童白血病/淋巴瘤研究组的AML-D11试验前瞻性评估了诱导后及化疗结束时流式细胞术(FCM)和GATA1靶向深度测序检测的微小残留病(MRD)对唐氏综合征髓系白血病(ML-DS)的预后价值。78例符合条件,76例按形态学归为标准风险组;标准风险组中诱导后FCM-MRD阳性5/65例、GATA1-MRD阳性7/59例,阴性组3年无事件生存(EFS)和总生存(OS)显著优于阳性组。诱导后任一方法检测MRD阳性是预测复发的显著预后因素。
要点
- 诱导后FCM-MRD阳性者3年EFS为60.0%,阴性者为95.0%。
- 诱导后GATA1-MRD阳性者3年EFS为57.1%,阴性者为98.1%。
- FCM-MRD与EFS关联的校正风险比为14.67(p=0.01)。
核心结论
- 诱导后FCM或GATA1检测的MRD阳性是ML-DS复发的显著预后因素。
研究设计与样本
- 日本儿童白血病/淋巴瘤研究组AML-D11试验的前瞻性研究,共78例 eligible,76例按形态学归为标准风险组。
主要发现
- 标准风险组中诱导后FCM-MRD阳性5/65例,GATA1-MRD阳性7/59例。
- FCM-MRD阴性组3年EFS为95.0%、OS为96.7%,阳性组分别为60.0%和80.0%。
- GATA1-MRD阴性组3年EFS和OS均为98.1%,阳性组分别为57.1%和71.4%。
- FCM-MRD与EFS关联的校正风险比为14.67(p=0.01)。
临床怎么用
- 对ML-DS标准风险患者,诱导后应通过FCM和/或GATA1检测MRD以识别高复发风险亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid leukemia of Down syndrome (ML-DS) is associated with good response to chemotherapy, resulting in favorable outcomes. However, no universal prognostic factors have been identified to date. To clarify a subgroup with high risk of relapse, the role of minimal residual disease (MRD) was explored in the AML-D11 trial by the Japanese Pediatric Leukemia/Lymphoma Study Group. MRD was prospectively evaluated at after induction therapy and at the end of all chemotherapy, using flow cytometry (FCM-MRD) and GATA1-targeted deep sequencing (GATA1-MRD). A total of 78 patients were eligible and 76 patients were stratified to the standard risk (SR) group by morphology. In SR patients, FCM-MRD and GATA1-MRD after induction were positive in 5/65 and 7/59 patients, respectively. Three-year event-free survival (EFS) and overall survival (OS) rates were 95.0% and 96.7% in the FCM-MRD-negative population, and 60.0% and 80.0% in the positive population. Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1% and 71.4% in the positive population. Adjusted hazard ratios for associations of FCM-MRD with EFS were 14.67 (p = 0.01). Detection of MRD by either FCM or GATA1 after initial induction therapy represents a significant prognostic factor for predicting ML-DS relapse.
引用
- Taga T, Tanaka S, Hasegawa D, et al. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia. 2021. PMID: 33589754. doi:10.1038/s41375-021-01157-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。